Allergies (Peanut)
Filter News
Found 27 articles
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im... -
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
4/19/2023
DBV Technologies announced that DBV has received written responses from the U.S. Food and Drug Administration on the regulatory path for investigational Viaskin™ Peanut 250 μg patch in toddlers ages 1 – 3 years-old with a confirmed peanut allergy.
-
Newly Published Study Demonstrates the Clinical Effectiveness of Machine Learning Used to Achieve Remission in Patients with Peanut Allergies
4/5/2023
The Food Allergy Institute announced that a peer reviewed paper authored by its founder Inderpal Randhawa, MD, has been published by the clinical journal PLOS ONE.
-
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
6/27/2022
ALK announced that it is initiating Phase I clinical development of its investigational SLIT-tablet for the treatment of peanut allergy.
-
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
4/6/2022
Intrommune Therapeutics today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow determination of the Maximum Tolerated Dose (MTD).
-
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients
2/9/2022
Prota Therapeutics, an Australian biotechnology company focused on the development of novel oral immunotherapy treatments, has achieved a significant milestone in the treatment of peanut allergy in children.
-
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
2/8/2022
Intrommune Therapeutics, Inc. today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy.
-
Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
1/26/2022
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut.
-
Angany Announces Vaccine Candidate to Treat Peanut Allergy
11/9/2021
Angany Inc., announces that it has entered into a partnering agreement with Dr. Wayne Shreffler, MD, PhD, Chief, Division of Pediatric Allergy & Immunology and Director of the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children, for a comprehensive series of preclinical studies of Angany's peanut allergy biologic candidate BP/AH-01.
-
Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA® in Clinical Practice in the U.S.
11/5/2021
Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA ® in Clinical Practice in the U.S.
-
FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals
9/16/2021
First-of-its-kind study will evaluate safety and efficacy of CNP-201, a nanoparticle containing peanut protein, in eliminating allergic responses
-
Intrommune Therapeutics Announces Arrival of Stuart Loesch as New CCO
9/8/2021
Intrommune Therapeutics, Inc. announced the appointment of Stuart Loesch as its new Chief Commercial Officer.
-
Advisory - One lot of pms-PROGESTERONE 100 mg capsules recalled because it may pose serious risks to individuals with severe peanut allergies
8/24/2021
Pharmascience Inc. is recalling one lot of pms-PROGESTERONE 100 mg capsules because the bottles may contain Akorn 100 mg progesterone gelatin capsules in addition to or instead of the intended pms-PROGESTERONE 100 mg gelatin capsules.
-
Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
8/4/2021
Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA ® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
-
New Life-Changing Test for Patients Diagnosed With Peanut Allergy
6/15/2021
AllerGenis announced the publication of a peer-reviewed study entitled, "Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping." Conducted by leading global experts in pediatric allergy and immunology from the Icahn School of Medicine at Mount Sinai, Stanford University and Kings College, the study found the AllerGenis peanut diagnostic blood test demonstrates accuracy significantly and statistically superior to all other established diagnostic tests.
-
Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
1/27/2021
Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten
-
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”Virtual Bio-Partnering Platform Connects Biotech Leaders with Investors; Partners
1/7/2021
Intrommune Therapeutics , a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will participate in BIO’s one-on-one virtual partnering meeting during the 39 th annual J.P. Morgan Healthcare Conference taking place January 11 – 14, 2021. The BIO One-on-One Partnering @ JPM platform enables partners and investors to schedule virtual video meetings with Intrommune executives. To
-
DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut. -
In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications. -
AllerGenis Begins Testing Patient Samples for Peanut Allergy Using Proprietary Epitope Mapping Technology
6/24/2020
AllerGenis LLC, a data-driven precision diagnostics company focused on food allergies, today announced the onset of operations at its Hatfield facility to test patient samples using its VeriMAP TM Peanut Diagnostic, a diagnostic solution for patients with peanut allergies. AllerGenis received full certification under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform its high complexity clinical l